Northwich

Researchers are investigating the effectiveness and safety of SAR442970 in adults with moderate to severe Ulcerative Colitis in a phase 2b randomized, double-blind study. The trial compares two different doses of SAR442970 against a placebo to see how well they work in treating this condition. The total study duration can last up to 168 weeks, including a long-term extension period for eligible participants. Participants will be randomly assigned to receive one of three treatments SAR442970 dose regimen A, SAR442970 dose regimen B, or a matching placebo, all given by subcutaneous injection. The study includes a treatment period lasting up to 158 weeks, followed by an open-label long-term extension phase of up to 104 weeks for those who qualify. Throughout the study, participants will undergo regular assessments to measure clinical remission using the modified Mayo Score at Week 16, as well as other outcomes such as endoscopic improvement, histological remission, and patient-reported outcomes. Safety will be monitored by tracking adverse events. Blood samples for drug concentration and antibodies will also be collected. The overall participation may last up to approximately 164 weeks.